Clinical Trial

A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
For Safety introduction phase，this study is to evaluate the safety and tolerability of LM-168 in combination with other anti-tumor treatment regimens in participants of advanced solid tumor trials, determine the maximum tolerated dose (MTD), and explore the recommended phase II dose (RP2D). For Dose expansion phase，this study is to evaluate the preliminary antitumor activity of LM-168 in combination with other antitumor treatment regimens in participants of advanced solid tumor trials, measured by objective response rate (ORR)
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-31
Trial Details
NCT Number NCT07669415
Lead Sponsor LaNova Medicines Limited
Conditions Advanced Solid Tumor
Enrollment 108 participants
Start Date 2026-07-29
Primary Completion 2027-12-15 (estimated)
Study Completion 2028-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-30